Artificial Intelligence Clinical Genomics Interpretation Market Report 2025

The artificial intelligence clinical genomics interpretation market size has grown exponentially in recent years. It will grow from $1.35 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 28.5%. The growth in the historic period can be attributed to increasing adoption of artificial intelligence in healthcare, rising demand for personalized medicine, greater availability of genomic data, enhanced computational power for AI algorithms, and growing investment in AI-driven diagnostics.

The artificial intelligence clinical genomics interpretation market size is expected to see exponential growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 28.1%. The growth in the forecast period can be attributed to wider adoption of AI-powered genomic tools, rising demand for precision medicine, increasing integration of cloud-based analytics, growing government funding for genomics research, and expanded use of real-world data in clinical decision-making. Key trends in the forecast period include advancements in AI-driven predictive analytics, innovations in multi-omics data integration, integration of AI with electronic health records, progress in real-time genomic interpretation, and development of explainable AI for clinical genomics.

The growing demand for personalized medicine is expected to support the expansion of the artificial intelligence clinical genomics interpretation market. Personalized medicine is a healthcare approach that customizes diagnosis, treatment, and prevention strategies based on an individual’s genetic, environmental, and lifestyle characteristics. This approach is gaining traction due to its ability to provide more effective treatments by aligning therapies with specific genetic profiles, resulting in improved outcomes and reduced side effects. Artificial intelligence clinical genomics interpretation contributes by quickly processing complex genomic data to identify accurate, patient-specific treatment options, enhancing therapeutic effectiveness and minimizing trial-and-error in medical decision-making. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. This trend supports the growth of the artificial intelligence clinical genomics interpretation market.

Leading companies in the artificial intelligence clinical genomics interpretation market are investing in scalable innovations to support large-scale genomic studies, enabling high-throughput data processing, improved accuracy, and accelerated identification of biomarkers and therapeutic targets. Scalability refers to an AI system’s ability to efficiently analyze vast and complex genomic datasets without loss of speed or accuracy, which is increasingly important as data volume grows. For example, in December 2024, QIAGEN, a life sciences company based in Germany, introduced an AI-powered update to its Ingenuity Pathway Analysis platform, aimed at automating the interpretation of complex biological data. This update uses artificial intelligence to identify relevant genes, pathways, and molecular networks involved in disease processes and integrates QIAGEN’s Biomedical Knowledge Base, which contains hundreds of millions of AI-derived relationships, to support accurate, data-driven insights.

In May 2025, GeneDx, a US-based provider of genomic diagnostic testing and precision medicine services, acquired Fabric Genomics for an undisclosed sum. This acquisition is intended to enhance GeneDx’s artificial intelligence clinical genomics interpretation capabilities, particularly in areas such as rare disease diagnosis and neonatal genetic screening. Fabric Genomics, also based in the US, is a developer of AI-driven genomic data interpretation software and clinical decision support tools used by healthcare providers and laboratories.

Major players in the artificial intelligence clinical genomics interpretation market are F. Hoffmann-La Roche AG, NVIDIA Corporation, Illumina Inc., QIAGEN N.V., Tempus Labs Inc., GeneDx Inc., Freenome Inc., NantHealth Inc., SOPHiA GENETICS SA, Genomenon Inc., DNAnexus Inc., Lifebit Biotech Ltd., Deep Genomics Inc., SpeeDx Pty Ltd, PierianDx Inc., Genuity Science Inc., Karius Inc., FDNA Inc., SeqOne Genomics Inc., Nostos Genomics Inc.

North America was the largest region in the artificial intelligence clinical genomics interpretation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence clinical genomics interpretation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the artificial intelligence clinical genomics interpretation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Artificial intelligence (AI) clinical genomics interpretation refers to the application of AI-driven algorithms and computational models to analyze and interpret genomic data for clinical purposes. It facilitates the identification of genetic variants, prediction of disease risk, and guidance for personalized treatment decisions.

The primary components of AI clinical genomics interpretation are software and services. The software includes AI-powered platforms and applications designed for automated analysis, interpretation, and reporting of complex clinical genomic data. These solutions can be implemented in cloud-based or on-premises environments. Applications cover areas such as oncology, rare diseases, pharmacogenomics, infectious diseases, and more, while key end-users include hospitals and clinics, research institutions, diagnostic laboratories, and other organizations engaged in clinical genomics.

The artificial intelligence clinical genomics interpretation market research report is one of a series of new reports that provides artificial intelligence clinical genomics interpretation market statistics, including the artificial intelligence clinical genomics interpretation industry global market size, regional shares, competitors with the artificial intelligence clinical genomics interpretation market share, detailed artificial intelligence clinical genomics interpretation market segments, market trends, and opportunities, and any further data you may need to thrive in the artificial intelligence clinical genomics interpretation industry. This artificial intelligence clinical genomics interpretation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence clinical genomics interpretation market includes of revenues earned by entities by providing services such as variant interpretation services, pharmacogenomics interpretation services, and tumor genomic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.